How to Navigate Ecosystem Connect NEW Distinguished Investigators 
Global Conferences RLT Education RLT Components Sponsors Trial Stats
Global Conferences RLT Education RLT Components Sponsors Trial Stats 
How to NavigateNEW Ecosystem Connect Distinguished Investigators Global Conferences RLT Education RLT Components Sponsors Trial Stats Dictionary About Us Our Values
Contact XCancer
Luke Nordquist, MD, FACP, CEO
drluke@xcancer.comTony Romero, MS, CCRC, Director of Research
tromero@gucancer.com
Study of 89Zr-girentuximab for PET Imaging of Solid Tumors Likely to Express High Levels of CAIX
Description:
A prospective, open-label, phase 2 study to explore CAIX expression through 89Zirconium-labelled girentuximab deferoxamine (89Zr-girentuximab) PET/CT imaging in patients with solid tumors.
Sponsor:
Telix PharmaceuticalsPhase:
Phase 2
Contacts:
Kavita Vadaliglobal-clinicaltrials@telixpharma.com
+61 3 9093 3808
Government Study Link:
NCT05563272 - Click here to see study onClinicalTrials.gov
Isotope(s):
ZIRCONIUM-89
Radioisotope: Zr89
Theranostic Role: PET Imaging
T1/2 (Half-Life): 78 Hours
Decay Mode: POSITRON β+ (22%), ELECTRON CAPTURE (76%), GAMMA
Energy: max 0.9 MeV, E mean 397 keV, Gamma 511 keV
Range: N/A
Decay Daughters: Y89 (Stable)
Status: Clinical Trials Only
Target(s):
Inclusion
- Histologically or cytologically proven solid tumors
- Male or female >= 18 years old
- At least one non-CNS, measurable target lesion per RECIST 1.1 documented at conventional imaging within 30 days prior
Exclusion
- Previous administration of any radionuclide within 10 half-lives prior to administration of 89Zr-girentuximab
- Exposure to any antineoplastic treatment within 14 days from planned administration
- Exposure to any CAIX-targeting compound in the last 3 months
Patient Education
Patient Education Not Yet Provided
Locations
Loading...
Share your feedback
Help us improve your experience